Track topics on Twitter Track topics that are important to you
Vir Biotechnology has joined the public markets, raising $142.9 million to support clinical tests of its infectious disease drugs. The San Francisco firm offered 7.1 million shares priced at $20 each, which was the low end of the $20 to $22 range that it had planned. Vir shares are expected to start trading later today […]
Original Article: Vir Bio’s IPO Brings In $143M for Tests of Hepatitis B Drug and MoreNEXT ARTICLE
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...